These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25120322)

  • 21. Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus.
    Tan EZ; Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2021 Mar; 36(3):751-757. PubMed ID: 32583444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy.
    Perazzo H; Cardoso SW; Yanavich C; Nunes EP; Morata M; Gorni N; da Silva PS; Cardoso C; Almeida C; Luz P; Veloso VG; Grinsztejn B
    J Int AIDS Soc; 2018 Nov; 21(11):e25201. PubMed ID: 30394678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome.
    Mikolasevic I; Milic S; Orlic L; Stimac D; Franjic N; Targher G
    J Diabetes Complications; 2016; 30(7):1347-53. PubMed ID: 27324703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
    Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
    World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
    Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic Steatosis in Chronic Hepatitis B as Measured by Controlled Attenuation Parameter: Frequency and Distribution.
    Nan S; Liang Y; Qu Y; Liu F; Wang L; Li T
    J Coll Physicians Surg Pak; 2019 Oct; 29(10):937-941. PubMed ID: 31564265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of Uric Acid With Liver Steatosis and Fibrosis Applying Vibration Controlled Transient Elastography in the United States: A Nationwide Cross-Section Study.
    Duan H; Zhang R; Chen X; Yu G; Song C; Jiang Y; He Y; Wan H; Shen J
    Front Endocrinol (Lausanne); 2022; 13():930224. PubMed ID: 35813625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-time Tissue Elastography for Assessment of Liver Stiffness in Adults Without Known Liver Disease.
    Hu Y; Gong HY; Lin HJ
    J Ultrasound Med; 2015 Oct; 34(10):1895-900. PubMed ID: 26384610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis.
    Bader RM; Jonas MM; Mitchell PD; Wiggins S; Lee CK
    J Cyst Fibros; 2019 Mar; 18(2):280-285. PubMed ID: 30509601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
    Ciardullo S; Monti T; Perseghin G
    Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
    de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
    J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis activity should be considered a confounder of liver stiffness measured with MR elastography.
    Ichikawa S; Motosugi U; Nakazawa T; Morisaka H; Sano K; Ichikawa T; Enomoto N; Matsuda M; Fujii H; Onishi H
    J Magn Reson Imaging; 2015 May; 41(5):1203-8. PubMed ID: 24889753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C.
    Conti F; Serra C; Vukotic R; Fiorini E; Felicani C; Mazzotta E; D'Errico A; Verucchi G; Lenzi M; Andreone P
    Liver Int; 2017 Feb; 37(2):187-195. PubMed ID: 27369740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic syndrome, hepatic fibrosis, and steatosis diagnosed by liver stiffness measurement and controlled attenuation parameter after liver transplantation: the impact on long-term survival.
    Eshraghian A; Fattahi MR; Taghavi A; Shamsaeefar A; Mansoorian M; Kazemi K; Nikeghbalian S; Malek-Hosseini SA
    Expert Rev Gastroenterol Hepatol; 2022 Oct; 16(10):1003-1009. PubMed ID: 36254767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population.
    Ciardullo S; Monti T; Grassi G; Mancia G; Perseghin G
    J Hypertens; 2021 Aug; 39(8):1621-1627. PubMed ID: 33657584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
    Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
    Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transient elastography for assessment of fibrosis and steatosis of liver grafts from brain-death donors.
    Liu WY; Wang JH; Guo Y; Wang X; Wu XD; Xu CS; Zhao Y; Zang YJ
    Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):155-161. PubMed ID: 31992509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students.
    Nastasa R; Stanciu C; Zenovia S; Singeap AM; Cojocariu C; Sfarti C; Girleanu I; Chiriac S; Cuciureanu T; Huiban L; Muzica CM; Trifan A
    Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
    Siddiqui MS; Vuppalanchi R; Van Natta ML; Hallinan E; Kowdley KV; Abdelmalek M; Neuschwander-Tetri BA; Loomba R; Dasarathy S; Brandman D; Doo E; Tonascia JA; Kleiner DE; Chalasani N; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):156-163.e2. PubMed ID: 29705261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.